|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||0.4200 - 0.4200|
|52-week range||0.3200 - 1.0000|
|Beta (5Y monthly)||1.82|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
A look at the shareholders of Futura Medical plc ( LON:FUM ) can tell us which group is most powerful. We can see that...
GUILDFORD, England, August 31, 2022--Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces positive results from the confirmatory Phase 3 clinical study, "FM71" for MED3000, an investigational therapy for the treatment of erectile dysfunction ("ED").